Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial
Zarif Yeganeh M, Vakili M, Shahriari-Ahmadi A, Nojomi M
Iranian journal of public health · 6 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2016-01-01 · Iran J Public Health · vol. 45 · número 1 · págs. 54–62
- Editorial
- National Institutes of Health
- Citado
- 14 citas · más que el 79% de estudios similares · 1.4× el promedio de su campo
- Referencias
- 43 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Chemotherapy-induced organ toxicity mitigation · Magnesium in Health and Disease · Silymarin and Mushroom Poisoning
- Palabras clave
- Hypomagnesemia, Medicine, Cisplatin, Randomized controlled trial, Chemotherapy, Internal medicine, Gastroenterology, Cancer, Magnesium, Chemistry
4 autores
- Maryam Zarif Yeganeh🇮🇷Rasool Akram Hospital
- Masoud Vakili🇮🇷Rasool Akram Hospital
- Ali Shahriari-Ahmadi🇮🇷Rasool Akram Hospital
- Marzieh Molavi Nojomi🇮🇷Iran University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Hypomagnesaemia is one of the main side effects of cisplatin-based chemotherapy regimens in cancer patients. The aim of the current investigation was to evaluate the effect of oral magnesium oxide (MgO) supplementation on cisplatin-induced hypomagnesemia.
Methods
This parallel-randomized controlled, open label trial was conducted in a hospital of Iran University of Medical Sciences in Tehran between December 2009 and May 2011. Participants were 69 adult patients with newly diagnosed non- leukemia neoplasms candidate for starting cisplatin-based chemotherapy. Oral MgO supplement according to cisplatin dose (500 mg MgO per 50 mg/m(2) of cisplatin) as 2-3 divided daily doses was started after completion of each chemotherapy cycle and continued to the next cycle for the intervention group. Patients in the control group did not receive any supplementation. Serum magnesium (Mg) was measured before each chemotherapy cycle. The main outcome was measuring serum Mg change and hypomagnesaemia rate during chemotherapy treatment.
Results
Sixty-two participants (31 intervention- 31 controls) enrolled into the study. Serum Mg levels showed significant difference between the two groups (P=0.01). There was a significant decrease in serum Mg of the control group (P=0.001). At the end of follow-up period prevalence of hypomagnesaemia in the intervention group was 10.7% versus 23.1% in the control group.
Conclusion
Continuously oral supplementation with MgO according to cisplatin dose (500 mg MgO per 50 mg/m(2) cisplatin) as 2-3 divided daily doses at rest days between chemotherapy cycles reduces the decline in serum Mg levels and also the prevalence of hypomagnesaemia in cancer patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.